Stock Report

Glenmark Pharmaceuticals Announces Q1 FY27 Results

Posted On : 2026-08-01 14:25:55( TIMEZONE : IST )

Highlights

- India Formulations revenue up by 15.5% YoY at Rs. 14,321 million
- North America revenue grew by 41.1% YoY to Rs. 10,974 million (Includes deferred outlicensing income recognition for ISB 2001)
- Europe revenue grew by 11.9% YoY to Rs.7,472 million
- Emerging Markets revenue up by 27.7% YoY to Rs. 7,304 million
- EBITDA of Rs. 8,048 million, 38.6% YoY growth, with an EBITDA margin of 20.03%
- Profit After Tax (PAT) of Rs. 4,828 million, with PAT margin of 11.8%

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, today announced its financial results for the first quarter ended June 30, 2026. For the first quarter of FY 2027, Glenmark's consolidated revenue was Rs. 40,185 million as against Rs. 32,644 million in the corresponding quarter last year, recording an overall growth of 23.1% YoY.

EBITDA was Rs. 8,048 million in the quarter ended June 30, 2026, registering 38.6% YoY growth and an EBITDA margin of 20.03%. Profit After Tax (PAT) for the quarter was Rs. 4,828 million, with a PAT margin of 11.8%.

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, "We have started FY2027 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. India continued to outperform the market, North America delivered robust underlying growth driven by our first-tomarket respiratory launches, and Emerging Markets sustained strong momentum, underscoring the strength of our diversified global business.

The results reinforce the direction of Glenmark's next phase: strengthening our core businesses while expanding our differentiated specialty and innovation-led platforms. With RYALTRIS® continuing to grow globally, WINLEVI® gaining traction across Europe, and further progress across our oncology portfolio and IGI's pipeline, we remain focused on disciplined execution, sustainable and profitable growth and creating long-term value."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 2233.30 as compared to the previous close of Rs. 2191.05. The total number of shares traded during the day was 22582 in over 2492 trades.

The stock hit an intraday high of Rs. 2257.15 and intraday low of 2192.40. The net turnover during the day was Rs. 50492186.00.